免疫抑制：髓源抑制性细胞的特征。
Immune suppression: the hallmark of myeloid derived suppressor cells.
机构信息
Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Maryland 20892, USA.
出版信息
Immunol Invest. 2012;41(6-7):581-94. doi: 10.3109/08820139.2012.680635.
Abstract
Myeloid derived suppressor cells (MDSC) are heterogeneous cell population consisting of myeloid progenitor cells and immature myeloid cells. These cells have essential immunoregulatory role in tumor bearing hosts and under different inflammatory conditions. No specific marker has been described to identify MDSC, which leaves their suppressor activity as their only hallmark function. In this review, we discuss the current in vivo and in vitro developed assays for elucidation of MDSC function and describe the discrepancies between murine and human MDSC in regard to their suppressor function. We also discuss antigen specificity of MDSC function and approaches to determine the effector function of these cells in vivo. Finally, we summarize different approaches currently being employed to target MDSC with the aim to enhance immune based therapies.
摘要
髓系来源的抑制细胞（MDSC）是由髓系祖细胞和未成熟髓系细胞组成的异质性细胞群体。这些细胞在荷瘤宿主和不同炎症条件下具有重要的免疫调节作用。目前还没有描述用于鉴定 MDSC 的特异性标志物，因此其抑制活性是其唯一的标志性功能。在这篇综述中，我们讨论了目前用于阐明 MDSC 功能的体内和体外开发的测定方法，并描述了在抑制功能方面，鼠类和人类 MDSC 之间的差异。我们还讨论了 MDSC 功能的抗原特异性以及确定这些细胞在体内的效应功能的方法。最后，我们总结了目前用于靶向 MDSC 的不同方法，旨在增强基于免疫的治疗。
相似文献
1
Immune suppression: the hallmark of myeloid derived suppressor cells.免疫抑制：髓源抑制性细胞的特征。
Immunol Invest. 2012;41(6-7):581-94. doi: 10.3109/08820139.2012.680635.
2
Negative regulation of myeloid-derived suppressor cells in cancer.癌症中髓源抑制性细胞的负调控。
Immunol Invest. 2012;41(6-7):562-80. doi: 10.3109/08820139.2012.685538.
3
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.髓系来源的抑制细胞与抗肿瘤 T 细胞：复杂的关系。
Immunol Invest. 2012;41(6-7):595-613. doi: 10.3109/08820139.2012.673191.
4
Guest editorial.特邀社论。
Immunol Invest. 2012;41(6-7):555-61. doi: 10.3109/08820139.2012.703914.
5
Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses.MDSC 介导的免疫抑制的分子机制研究进展：为新的工作假设铺平道路。
Immunol Invest. 2012;41(6-7):722-37. doi: 10.3109/08820139.2012.678023.
6
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives.髓源性抑制细胞在癌症中对 L-精氨酸的代谢：T 细胞抑制的机制和治疗前景。
Immunol Invest. 2012;41(6-7):614-34. doi: 10.3109/08820139.2012.680634.
7
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.髓源性抑制细胞依附于生理性 STAT3 对 STAT5 的依赖性造血编程，建立了多种肿瘤介导的免疫逃避机制。
Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745.
8
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.COX-2 抑制可改善免疫疗法，并与间皮瘤中髓样来源抑制细胞数量减少有关。塞来昔布影响 MDSC 功能。
BMC Cancer. 2010 Aug 30;10:464. doi: 10.1186/1471-2407-10-464.
9
Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.脑胶质瘤中的髓源性抑制细胞（MDSCs）与胶质瘤的发生发展。
Immunol Invest. 2012;41(6-7):658-79. doi: 10.3109/08820139.2012.689591.
10
The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.CD244 信号在肿瘤微环境免疫细胞中的新兴作用。
Front Immunol. 2018 Nov 28;9:2809. doi: 10.3389/fimmu.2018.02809. eCollection 2018.
引用本文的文献
1
Modulating the tumor microenvironment: The role of traditional Chinese medicine in improving lung cancer treatment.调节肿瘤微环境：中药在改善肺癌治疗中的作用。
Open Life Sci. 2025 May 20;20(1):20251100. doi: 10.1515/biol-2025-1100. eCollection 2025.
2
Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.发现一种新型小分子作为用于癌症免疫治疗的CD47/SIRPα和PD-1/PD-L1双重抑制剂。
Cell Commun Signal. 2024 Mar 11;22(1):173. doi: 10.1186/s12964-024-01555-4.
3
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.单细胞 RNA 测序分析患者髓系来源抑制细胞及对布鲁顿酪氨酸激酶抑制的反应。
Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572.
4
Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype.癌症患者血液中的免疫抑制性低密粒细胞表现出成熟的表型。
Life Sci Alliance. 2023 Nov 6;7(1). doi: 10.26508/lsa.202302332. Print 2024 Jan.
5
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.沙利度胺在胶质母细胞瘤治疗中的潜在应用：最新简要概述。
Metabolites. 2023 Apr 11;13(4):543. doi: 10.3390/metabo13040543.
6
Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.乙醇消融疗法在小鼠乳腺癌模型中引发免疫介导的抗肿瘤效应。
Cancers (Basel). 2022 Sep 25;14(19):4669. doi: 10.3390/cancers14194669.
7
Monocytic myeloid-derived suppressive cells mitigate over-adipogenesis of bone marrow microenvironment in aplastic anemia by inhibiting CD8 T cells.单核细胞/髓系来源的抑制性细胞通过抑制 CD8 T 细胞减轻再生障碍性贫血骨髓微环境的过度脂肪生成。
Cell Death Dis. 2022 Jul 18;13(7):620. doi: 10.1038/s41419-022-05080-5.
8
Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy?肿瘤相关巨噬细胞作为主要免疫细胞，是免疫冷肿瘤——胶质瘤治疗中不可或缺的靶点吗？
Front Cell Dev Biol. 2021 Jul 21;9:706286. doi: 10.3389/fcell.2021.706286. eCollection 2021.
9
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.髓源性抑制细胞导致的免疫检查点抑制剂耐药：血液系统恶性肿瘤的新治疗靶点
J Clin Med. 2021 Apr 28;10(9):1919. doi: 10.3390/jcm10091919.
10
Tumor-Associated Macrophages-Implications for Molecular Oncology and Imaging.肿瘤相关巨噬细胞——对分子肿瘤学和成像的影响
Biomedicines. 2021 Apr 2;9(4):374. doi: 10.3390/biomedicines9040374.
本文引用的文献
1
S100A9 a new marker for monocytic human myeloid-derived suppressor cells.S100A9 是单核细胞来源的人类髓系来源的抑制细胞的新标志物。
Immunology. 2012 Jun;136(2):176-83. doi: 10.1111/j.1365-2567.2012.03566.x.
2
Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling.抗原特异性 CD4(+) T 细胞通过 MHC Ⅱ类分子逆向信号调节肿瘤中髓系来源抑制细胞的功能。
Cancer Res. 2012 Feb 15;72(4):928-38. doi: 10.1158/0008-5472.CAN-11-2863. Epub 2012 Jan 11.
3
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.癌症患者中髓源抑制性细胞的表型、功能及临床意义。
Cancer Immunol Immunother. 2012 Feb;61(2):255-263. doi: 10.1007/s00262-011-1161-9. Epub 2011 Nov 27.
4
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.肿瘤浸润髓样细胞诱导小鼠肿瘤细胞对细胞毒性 T 细胞的耐药性。
J Clin Invest. 2011 Oct;121(10):4015-29. doi: 10.1172/JCI45862. Epub 2011 Sep 12.
5
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells.人类 Th17 细胞和 iTregs 的可塑性由不同的髓系细胞亚群协调。
Blood. 2011 Jun 16;117(24):6532-41. doi: 10.1182/blood-2010-11-317321. Epub 2011 Apr 14.
6
Antigen specificity of immune suppression by myeloid-derived suppressor cells.髓系来源抑制细胞的免疫抑制的抗原特异性。
J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12.
7
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.髓源性抑制细胞表达死亡受体 Fas，并在 T 细胞表达 FasL 时发生凋亡。
Blood. 2011 May 19;117(20):5381-90. doi: 10.1182/blood-2010-11-321752. Epub 2011 Mar 30.
8
MDSC in autoimmunity.髓系来源抑制细胞在自身免疫中的作用。
Int Immunopharmacol. 2011 Jul;11(7):789-93. doi: 10.1016/j.intimp.2011.01.026. Epub 2011 Feb 21.
9
Improving cancer immunotherapy by targeting tumor-induced immune suppression.通过靶向肿瘤诱导的免疫抑制来改善癌症免疫疗法。
Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5.
10
Myeloid derived suppressor cells in human diseases.髓系来源的抑制细胞在人类疾病中的作用。
Int Immunopharmacol. 2011 Jul;11(7):802-7. doi: 10.1016/j.intimp.2011.01.003. Epub 2011 Jan 13.
Zotero 插件